Applied Molecular Transport IncAMTIannounced topline Phase 2 results from the LOMBARD monotherapy trial for AMT-101 in biologic-naïve and experienced patients with moderate-to-severe ulcerative colitis (UC).
The clinical remission (CR) rate in patients treated with AMT-101 monotherapy was 17.1% (12/70 patients) compared to a CR rate of 20.0% (7/35 patients) with placebo, which was above the company’s baseline assumption for placebo CR rates based on published data in moderate-to-severe UC patients.
The company noted similar clinical remission rates observed in patients receiving AMT-101 monotherapy compared to placebo at week 12.
“We will be seeking a partner to advance AMT-101 in chronic pouchitis into Phase 3 and look forward to presenting additional pouchitis data at the European Crohn’s and Colitis Organisation meeting in March 2023,” said Bittoo Kanwar, chief medical officer of AMT.
Tahir Mahmood, CEO & co-founder of AMT, added, “Our platform technology has generated two clinical assets, and we look forward to advancing AMT-126, an oral fusion of AMT’s proprietary carrier molecule and IL-22, which is a validated target, into a planned Phase 1b trial in UC.”
“We remain focused on stepwise execution and will be judicious in deploying our resources and extending our cash runway,” Mahmood added.
AMT-101 was well-tolerated. Treatment-emergent adverse events (TEAEs) were mainly mild to moderate and were generally balanced between the two arms.
Price Action: AMTI shares closed 10.7% down at $0.92 during after-hours trading on Thursday.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
